NOXXON Pharma N.V. announces that due to supply-chain issues affecting its drug-supply manufacturer, the start date of its two upcoming NOX-A12 clinical trials will be delayed by up to 3 months until Third Quarter 2022. The affected trials are the Phase 2 trial (OPTIMUS) with NOX-A12 in combination with MSD's (Merck & Co. Inc., Kenilworth, N.J. USA) anti-PD-1 therapyKeytruda? (pembrolizumab) as second-line therapy in pancreatic cancer, and the planned pivotal Phase 2/3 trial of NOX-A12 in combination with radiotherapy in first-line brain cancer (glioblastoma) patients. Due to a shortage in the US of dichloroacetic acid, a key chemical reagent necessary to synthesize NOX-A12, NOXXON has been informed by its contract active ingredient manufacturer that the NOX-A12 batches needed to initiate these two studies will only be available in Second Quarter 2022 with first patients therefore expected to be dosed in early August 2022. These delays have impacted the overall approval timelines of NOX-A12 in glioblastoma, pushing it into early 2026, while market approval in pancreatic cancer remains unchanged and is planned in 2027.